Humira

$550

Active ingredient: adalimumab 40 mg
Manufacturer: AbbVie
2 syringes

Description

Humira (adalimumab) is an anti-TNF monoclonal antibody that currently treats:

Rheumatoid Arthritis: Humira (adalimumab) is indicated, alone or in combination with methotrexate or other non-biologic DMARDs, for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.

Juvenile Idiopathic Arthritis: Humira (adalimumab) is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.

Psoriatic Arthritis: (adalimumab) is indicated, alone or in combination with non-biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.

Ankylosing Spondylitis: (adalimumab) is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.

Adult Crohn’s Disease: (adalimumab) is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy, and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

Pediatric Crohn’s Disease: (adalimumab) is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.

Ulcerative Colitis: (adalimumab) is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6-mercaptopurine. The effectiveness of Humira (adalimumab) has not been established in patients who have lost response to or were intolerant to anti-TNF agents.

Plaque Psoriasis: Humira (adalimumab) is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Humira (adalimumab) should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Hidradenitis Suppurativa: Humira (adalimumab) is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa.

Uveitis: Humira (adalimumab) is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients.

Common side effects of Humira include:

  • injection site reactions (redness, itching, pain, bruising, swelling, or bleeding),
  • headache,
  • suffy nose,
  • sinus pain, or
  • stomach pain.

Contact us